22 January 2026
22 January 2026, Geneva
The Medicines Patent Pool (MPP) welcomes Coefficient Giving as a new philanthropic funder and strategic partner, supporting the expansion of MPP’s voluntary licensing work into non-communicable diseases over the next three years.
The funding will enable MPP to build on its voluntary licensing approach, with an initial focus on GLP-1 agonist medicines for diabetes and obesity, as well as priority cancer therapies—including treatments for breast, prostate, and lung cancers and selected immunotherapies—where innovation has advanced rapidly but affordability and availability remain major barriers in many low- and middle-income countries (LMICs).
Charles Gore, Executive Director of MPP, said: “Non-communicable diseases now account for the majority of the global disease burden, yet access to the most effective new treatments remains profoundly unequal. We are truly grateful for Coefficient Giving’s support that will allow us to do more—deepening our engagement with partners and accelerating efforts to translate innovation into affordable and timely access for people living in LMICs.”
Ray Kennedy, of Coefficient Giving said: “Improving access to better treatments for patients in LMICs is central to Coefficient Giving’s work. We are excited about the potential of GLP-1 medicines in the non-communicable disease space and the opportunity to help translate scientific advances into real-world impact.”
MPP will work with patent holders, generic manufacturers, governments, communities, and global health partners to identify priority medicines, develop disease-specific access strategies, and secure public health–oriented voluntary licences that expand sustainable supply and affordability.
Through this partnership, MPP aims to demonstrate that access to cutting-edge non-communicable disease medicines and therapeutics in LMICs is both feasible and sustainable, and to contribute to a broader shift in industry norms so that innovative medicines are launched with access strategies that reach all who could benefit, regardless of where they live.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.